Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells

Atherosclerosis

Volumn 136, Issue 1, 1998, Pages 51-57

  Rikitake, Yoshiyuki ^a   Hirata, Ken Ichi ^a   Kawashima, Seinosuke ^a   Akita, Hozuka ^a   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Inducible NOS; LDL oxidation; Nitric oxide; Vascular smooth muscle cell

Indexed keywords

CYTOKINE; LINSIDOMINE; LOW DENSITY LIPOPROTEIN; N ACETYL S NITROSOPENICILLAMINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECOMBINANT INTERLEUKIN 1BETA; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL CULTURE; CONTROLLED STUDY; IMMUNOMODULATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELLS, CULTURED; COPPER; ELECTROPHORESIS, AGAR GEL; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; KINETICS; LIPOPROTEINS, LDL; MICE; MOLSIDOMINE; MUSCLE, SMOOTH, VASCULAR; NA(+)-K(+)-EXCHANGING ATPASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; PENICILLAMINE; RATS; S-NITROSO-N-ACETYLPENICILLAMINE;

EID: 0031825004     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00186-X     Document Type: Article

References (43)

1. Brown M.S., Goldstein J.L. Atherosclerosis: scavenging for receptors. Nature. 343:1990;508-509.
2. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.D., Witztum J.L. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenecity. New Engl J Med. 320:1989;915-924.
3. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
4. Parthasarathy S., Printz D.J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Atherosclerosis. 6:1986;505-510.
5. Henriksen T., Mahoney E.M., Steinberg D. Macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition of receptors for acetylated low density lipoprotein. Proc Natl Acad Sci USA. 78:1981;6499-6503.
6. Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of biologically modified LDL. Atherosclerosis. 3:1983;149-159.
7. Moyer C.F., Sajuthi D., Tulli H., Williams J.K. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol. 138:1991;951-960.
8. Barath P., Fishbein M.C., Cao J., Berenson J., Helfant R.H., Forrester J.S. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol. 65:1990;297-302.
9. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3015-3064.
10. Koide M., Kawahara Y., Nakayama I., Tsuda T., Yokoyama M. Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. J Biol Chem. 268:1993;24959-24966.
11. Nakayama I., Kawahara Y., Tsuda T., Okuda M., Yokoyama M. Angiotensin II inhibits cytokine-stimulated inducible nitric oxide synthase expression in vascular smooth muscle cells. J Biol Chem. 269:1994;11628-11633.
12. Buttery L.D.K., Springall D.R., Chester A.H., Evans T.J., Standfield N., Parums D.V., Yacoub M.H., Polak J.M. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 75:1996;77-85.
13. Malo-Ranta U., Ylä-Herttuala S., Metsä-Ketelä T., Jaakkola O., Moilanen E., Vuorinen P., Nikkari T. Nitric oxide donor GEA 3162 inhibits endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett. 337:1994;179-183.
14. Jessup W., Dean R.T. Autoinhibition of murine macrophage-mediated oxidation of low-density lipoprotein by nitric oxide synthesis. Atherosclerosis. 101:1993;145-155.
15. Rubbo H., Radi R., Trujillo M., Telleri R., Kalyanaraman B., Barnes S., Kirk M., Freeman B.A. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. J Biol Chem. 269:1994;26066-26075.
16. Hirata K., Miki N., Kuroda Y., Sakoda T., Kawashima S., Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res. 76:1995;958-962.
17. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
18. Steinbrecher U.P. Role of superoxide in endothelial cell modification of low-density lipoproteins. Biochim Biophys Acta. 959:1988;20-30.
19. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 15:1976;212-216.
20. Esterbauer H., Striegl G., Puhl H., Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 6:1989;67-75.
21. Hogg N., Kalyanaraman B., Joseph J., Struck A., Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett. 334:1993;170-174.
22. Hansson G.K., Geng Y.-J., Holm J., Hardhammar P., Wennmalm A., Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med. 180:1994;733-738.
23. Yao S., Ober J.C., Krishnaswami A.K., Ferguson J.J., Anderson H.V., Golino P., Buja L.M., Willerson J.T. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation. 86:1992;1302-1309.
24. Bath P.M.W., Hassall D.G., Gladwin A.-M., Palmer R.M.J., Martin J.F. Nitric oxide and prostacyclin: Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Artherioscler Thromb. 11:1991;254-260.
25. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777.
26. Cooke J.P., Singer A.H., Tsao P.S., Zera P., Rowan R.A., Billingham M.E. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 90:1992;1168-1172.
27. Candipan R.C., Wang B., Buitrago R., Tsao P.S., Cooke J.P. Regression or progression: dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 16:1996;44-50.
28. Berliner J.A., Territo M.C., Sevanian A., Ramin S., Kim J.A., Bamshad B., Esterson M., Fogelman A.M. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 85:1990;1260-1266.
29. Lehr H.A., Hubner C., Nolte D., Finckh B., Beisiegel U., Kohlschutter A., Messmer K. Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med. 191:1991;85-90.
30. Koschinsky T.C., Bunting C.E., Rutter R., Gries F.A. Increased growth stimulation of human vascular cells by serum from patients with primary hyper-LDL-cholesterolemia. Atherosclerosis. 63:1987;7-13.
31. Scott-Burden J., Resink T.J., Hahn W.A., Baur U., Box R.J., Buhler F.R. Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein. J Biol Chem. 264:1989;12582-12589.
32. Aviram M. Modified forms of low density lipoprotein affect platelet aggregation in vivo. Thromb Res. 53:1989;561-567.
33. Simon B.C., Cunningham L.D., Cohen R.A. Oxidized low-density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in pig coronary artery. J Clin Invest. 86:1990;75-79.
34. Yokoyama M., Hirata K., Miyake R., Akita H., Ishikawa Y., Fukuzaki H. Lysophosphatidylcholine: Essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biochem Biophys Res Commun. 168:1990;301-308.
35. Kugiyama M., Kerns S.A., Morrisett J.D., Roberts R., Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:1990;160-162.
36. Inoue N., Hirata K., Yamada M., Hamamori Y., Matsuda Y., Akita H., Yokoyama M. Lysophosphatidylcholine inhibits bradykinin-induced phosphoinositide hydrolysis and calcium transients in cultured bovine aortic endothelial cells. Circ Res. 71:1992;1410-1421.
37. Hirata K., Akita H., Yokoyama M. Oxidized low density lipoprotein inhibits bradykinin-induced phosphoinositide hydrolysis in cultured bovine aortic endothelial cells. FEBS Lett. 287:1991;181-184.
38. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA. 84:1987;7725-7729.
39. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for hypercholesterolemia. Proc Natl Acad Sci USA. 84:1987;5928-5931.
40. Bjorkham I., Henriksson-Freyschuss A., Breur U., Diczfalusy U., Berglund L., Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb. 11:1989;15-22.
41. Keaney J.F. Jr., Xu A., Cunningham D., Jackson T., Frei B., Vita J.A. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest. 95:1995;2520-2529.
42. Stephens N.G., Parsons A., Shofield P.M., Kelly F., Cheeseman K., Mitchinson M.J., Brown M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
43. Heinecke J.W., Baker L., Rosen H., Chait A. Superoxide-mediated modification of low density lipoprotein. J Clin Invest. 77:1986;757-761.